Taranabant
Taranabant is a cannabinoid receptor type 1 (CB1) antagonist that was developed by Merck & Co for the treatment of obesity. It is the inverse agonist of the CB1 receptor, as opposed to the antagonist, which means it produces the opposite effect to the natural ligand (in this case, the endocannabinoids).
History[edit | edit source]
Taranabant was first synthesized and studied by Merck & Co. The company initiated clinical trials for the drug in the early 2000s, with the aim of developing a new treatment for obesity. However, the development of Taranabant was discontinued in 2008 due to concerns about side effects, including depression and anxiety.
Mechanism of Action[edit | edit source]
Taranabant works by blocking the CB1 receptor, one of the two receptors in the endocannabinoid system. This system plays a key role in regulating energy balance and food intake. By blocking the CB1 receptor, Taranabant reduces appetite and increases energy expenditure, thereby promoting weight loss.
Clinical Trials[edit | edit source]
Several clinical trials were conducted to evaluate the efficacy and safety of Taranabant in the treatment of obesity. These trials showed that Taranabant could significantly reduce body weight in obese individuals. However, the trials also revealed that the drug could cause psychiatric side effects, including depression and anxiety. These findings led to the discontinuation of the development of Taranabant.
Side Effects[edit | edit source]
The most common side effects of Taranabant include nausea, vomiting, and diarrhea. The drug can also cause psychiatric side effects, such as depression and anxiety. These side effects were the main reason for the discontinuation of the development of Taranabant.
Current Status[edit | edit source]
As of now, Taranabant is not approved for use in any country. The development of the drug was discontinued in 2008 due to concerns about its side effects. However, research on the endocannabinoid system and its role in obesity continues, and new drugs targeting this system may be developed in the future.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
